Abcam, ab307729, Anti-eIF4A2 antibody [EPR27347-74] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal eIF4A2 antibody. Carrier free. Suitable for WB, IHC-P, ICC/IF, Flow Cyt (Intra), IP and reacts with Human, Recombinant fragment - Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27347-74,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:WB, Flow Cyt (Intra), IP, IHC-P, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The eIF4A2 also known as DDX2B functions as an RNA helicase with an ATP-dependent mechanism. It unwinds RNA secondary structures in the 5'UTR of mRNAs to facilitate ribosome binding. eIF4A2 belongs to the DEAD-box family of proteins and it has a molecular mass of approximately 46 kDa. It is ubiquitously expressed in various tissues indicating its broad role in cellular processes.
Biological function summary
EIF4A2 is integral to the initiation of protein synthesis. It acts as a core member of the eIF4F complex along with the cap-binding protein eIF4E and scaffold protein eIF4G. This complex enables the recruitment of ribosomes to mRNA an important step in translation initiation. eIF4A2 helps regulate the translation of specific mRNAs that are important for cell growth and proliferation affecting how cells respond to environmental stimuli.
Pathways
EIF4A2 plays a significant role in the mTOR and MAPK signaling pathways. In the mTOR pathway eIF4A2 controls the translation of mRNAs that drive cell growth and metabolism. It also interacts with other proteins such as mTORC1 and S6K which modulate these processes. Its involvement in the MAPK pathway links it with cell survival and stress responses emphasizing its interaction with proteins like MEK1/2 and ERK1/2 that further propagate these signals.
EIF4A2 has implications in cancer and neurodegenerative diseases. eIF4A2's overexpression has been associated with various cancers whereby it encourages oncogenic transformation through its role in synthesis of growth-related proteins. Moreover the helicase has links to Alzheimer's disease where it may influence disease progression by modulating synaptic plasticity proteins such as APP and tau important for neuronal function. The regulation by eIF4A2 of these proteins highlights its potential as a therapeutic target.